- Home
- BTAI
as 11-26-2025 3:42pm EST
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Founded: | 2017 | Country: | United States |
| Employees: | 37 | City: | NEW HAVEN |
| Market Cap: | 41.8M | IPO Year: | 2018 |
| Target Price: | $32.80 | AVG Volume (30 days): | 691.3K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.17 - $9.26 | Next Earning Date: | 11-12-2025 |
| Revenue: | $752,000 | Revenue Growth: | -66.96% |
| Revenue Growth (this year): | -67.7% | Revenue Growth (next year): | 544.99% |
Latest BioXcel Therapeutics Inc. News
BTAI Breaking Stock News: Dive into BTAI Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Looking at the Narrative for BioXcel Therapeutics After Fair Value Reset and Clinical Milestones
Zacks
15 days ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
15 days ago
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
GlobeNewswire
a month ago
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
GlobeNewswire
a month ago
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
GlobeNewswire
3 months ago
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
MT Newswires
4 months ago
BioXcel Therapeutics Gets Patent Allowance for Targeted Use of Igalmi in Bipolar, Schizophrenia Patients
GlobeNewswire
6 months ago
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Compare BTAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BTAI BioXcel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.